Alkermes Inc. (ALKS) announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension or XR-NTX for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Based on the positive results of this phase 3 study, Alkermes plans to file a supplemental New Drug Application or sNDA with the U.S. Food and Drug Administration in the first half of calendar 2010. XR-NTX, marketed by Alkermes as VIVITROL, is an opioid antagonist administered once-monthly by intramuscular injection and is approved in the U.S. for the treatment of alcohol dependence.
In addition to meeting the primary efficacy endpoint, the six-month phase 3 study met all secondary efficacy endpoints. Data from the intent-to-treat analysis show that the median patient taking XR-NTX had 90% opioid-free urine screens during the evaluation phase of the study and patients treated with XR-NTX demonstrated a significant reduction in opioid craving compared to placebo as measured by a visual analog scale. XR-NTX was generally well tolerated in the study and no patients on XR-NTX discontinued the study due to adverse events. The most common adverse events experienced by patients receiving XR-NTX during the study were nasopharyngitis and insomnia.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.